MedTrace Logo

A Study in the United States Using Electronic Medical Records (EMR) to Assess Effectiveness of Afatinib (Gilotrif) Following Pembrolizumab and Chemotherapy in the Treatment of Metastatic Squamous Cell Carcinoma of the Lung

NCT04552535 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2022-01-11

Study results available
· View outcomes & findings →

Summary

This study aims to characterize the profile and outcomes for patients with Squamous Cell Carcinoma of the Lung (SqCC) who progress on 1L pembrolizumab in combination with platinum based chemotherapy and receive afatinib as second line (2L) therapy.

Conditions

  • Squamous Non-small Cell Lung Cancer

Interventions

DRUG

Second line (2L) afatinib

Afatinib

DRUG

Second line chemotherapy

Chemotherapy

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-08
Primary Completion
2020-05-18
Completion
2020-05-18

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552535 on ClinicalTrials.gov